Wu A, Gao P, Wu N, et al. - Researchers investigated the prognostic worth of the percentage of mature monocyte in bone marrow (PMMBM) in a cohort of 216 myelodysplastic syndromes (MDS) patients in this retrospective study. Participants were split into elevated PMMBM group and the normal group by 6% PMMBM as the cut-off value. According to findings, a poor prognosis was reported in relation to increased PMMBM accompanied with higher frequency of IDH2 mutation. As a prognostic factor, PMMBM could provide assistance to IPSS-R (Revised International Prognostic Scoring System) to offer a convenient for measuring the prognosis of MDS cases particularly when their karyotype analysis fails.